Severe Aplastic Anemia (SAA) Clinical Trial
Official title:
A Phase 1/2 Study of REGN7257 (Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) in Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy
This study is researching an experimental drug called REGN7257 (called "study drug"). The study is focused on patients who have severe aplastic anemia (SAA), a disease of the bone marrow resulting in an impairment of the production of blood cells. The main purpose of this two-part study (Part A and Part B) is to test how safe and tolerable REGN7257 is in patients with SAA in which other Immunosuppressive therapies (ISTs) have not worked well. The study is looking at several other research questions to better understand the following properties of REGN7257: - Side effects that may be experienced by participants taking REGN7257 - How REGN7257 works in the body - How much REGN7257 is present in blood after dosing - If REGN7257 works to raise levels of certain blood counts after treatment - How quickly REGN7257 works to raise levels of certain blood counts - In patients for whom REGN7257 works to raise levels of certain blood counts after treatment, how many continue to show such a response throughout the study - If REGN7257 works to lower the number of platelet and red blood cell transfusions needed - How REGN7257 changes immune cell counts and composition - How the body reacts to REGN7257 and if it produces proteins that bind to REGN7257 (this would be called the formation of anti-drug antibodies [ADA])
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04328727 -
Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia
|
Phase 2 | |
| Completed |
NCT00604201 -
Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome
|
Phase 2 | |
| Completed |
NCT01891994 -
Extended Dosing With Eltrombopag for Severe Aplastic Anemia
|
Phase 2 | |
| Completed |
NCT00001626 -
Comparing Therapies for the Treatment of Severe Aplastic Anemia
|
Phase 2 | |
| Recruiting |
NCT03520647 -
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
|
Phase 2 | |
| Completed |
NCT01900119 -
A Description of Bacteria in the Mouths of Patients With Severe Aplastic Anemia
|
||
| Withdrawn |
NCT05323617 -
Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy
|
Phase 2 |